Sidekick Health is already working with pharma heavyweights Pfizer and Bayer on gamified apps that can be paired with drug therapies to improve patient outcomes – and says it is poised to announce three more in the coming months. The…
FDA approves first in vitro test for early Alzheimer’s disease
The US FDA has authorised a new test that can detect amyloid plaques in early-stage Alzheimer’s disease without the use of PET scans, which expose patients to radiation. Fujirebio Diagnostics’ Lumipulse G β-Amyloid Ratio (1-42/1-40) test has been cleared for…
Researchers Use CRISPR to Reset Anxiety, Alcohol Use Disorder
Researchers at the University of Illinois at Chicago have uncovered the possibility of utilizing gene editing to reverse a cause of anxiety and alcohol use disorder (AUD). The study, published by Science Advances, provides a new approach to a disorder that affects 15…
TCS introduces monitoring solution for clinical trials
The solution enables biopharmaceutical and CROs to detect risks linked to trials and sites using improved statistical algorithms. IT services, consulting and business solutions organisation Tata Consultancy Services (TCS) has introduced a risk-based monitoring solution for clinical trials. The swift and intuitive…
Thread acquires CureClick to improve trial awareness, access
Prior to the acquisition of CureClick, Thread acquired Modus Outcomes and inVibe. Decentralised clinical trial (DCT) technology and consulting service provider Thread has acquired US-based CureClick to improve the pathway from clinical trial awareness to access. Established in 2013, CureClick…
SNIPR BIOME commences dosing in Phase I trial of CRISPR-based therapy
The trial will analyse SNIPR001’s safety and tolerability and its effect on decreasing the colonisation of E. coli in the gut. SNIPR BIOME has initiated dosing of the first subjects with SNIPR001, an oral clustered regularly interspaced short palindromic repeats…
CATO SMS rebrands to become Allucent
The new name and branding come after a three-year series of strategic acquisitions. International biopharmaceutical services provide, CATO SMS has rebranded and became Allucent to aid in bringing advanced therapies to light. The latest move is aimed at underscoring the…
BeiGene, Zai Lab, Among Companies Facing Delisting From Wall Street
Five Chinese companies face potential delisting from Wall Street if they fail to comply with new audit orders from the U.S. Securities and Exchange Commission (SEC). The SEC said that Yum China, BeiGene, Zai Lab, HutchMed and ACM are all at risk if…
Rules of engagement: navigating around traps when recruiting clinical trials via social media
Pharma has a chance at redefining its relationship to the public, allowing for direct interaction with potential clinical trial participants via social media. But what’s the risk? Need to Know: Social media can be a powerful tool to directly advertise…
A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia
Connecticut-based BioXcel Therapeutics announced a win for artificial intelligence in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has approved a sublingual film drug that aims to reduce the occurrence of agitation episodes in patients diagnosed with bipolar disorder…
